Grifols (GIKLY) Cash & Equivalents Growth (5y) (2014 - 2025)

Grifols (GIKLY) Cash & Equivalents Growth (5y) (2014 - 2025) Analysis & Trends

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn
9	Novartis Ag	113.45 Bn	113.67 Bn	-
10	Grifols	-	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2025	5.96%
Dec 31, 2024	4.98%
Dec 31, 2023	-13.57%
Dec 31, 2022	-11.71%
Dec 31, 2021	25.94%
Dec 31, 2020	-11.21%
Sep 30, 2020	4.00%
Mar 31, 2020	-4.82%
Dec 31, 2019	-9.44%
Sep 30, 2019	-6.26%
Mar 31, 2019	-6.92%
Dec 31, 2018	4.11%
Sep 30, 2018	0.91%
Jun 30, 2018	4.98%
Mar 31, 2018	14.23%
Dec 31, 2017	11.20%
Jun 30, 2017	15.33%
Dec 31, 2016	16.05%
Sep 30, 2016	34.30%
Jun 30, 2016	1.66%